ReviewFrontiers in immunology2021

Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.

Dongfeng Feng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.